HJBR May/Jun 2026

HEALTHCARE JOURNAL OF BATON ROUGE I  MAY / JUN 2026 49 For weekly eNews updates and to read the journal online, visit HealthcareJournalBR.com Center, and UPMC Magee-Women’s Hospital (Pennsylvania). Once the trial is completed by the end of the year, the product, including trial data, will be submitted for FDA clearance. Brain Health Collaboratory Launched Cognito Therapeutics, a late clinical-stage neu- rotechnology company pioneering noninvasive neuroprotective therapies in neurodegenerative diseases is collaborating with Ochsner Health to launch a brain health collaboratory aimed at advancing new approaches to treating cognitive decline and Alzheimer’s disease. The collaboration establishes the Gulf South’s first statewide platform for noninvasive brain health innovation, combining Cognito’s investigational Spectris technology platform with Ochsner’s clinical network to explore new models for brain healthcare delivery throughout the region. A new 132,000-square-foot facility, the Debra H. and Robert J. Patrick Neuroscience Institute at Ochsner Medical Center in New Orleans, is set to open in late 2026, bringing Ochsner’s neurosciences programs under one roof. Ochsner and Cognito will work to develop a brain health index, a framework designed to better track cognitive health, disease progression, and treatment response in real-world care settings. The program will also explore opportunities to integrate Cognito’s investigational Spectris therapy into clinical care models for patients experiencing cognitive decline. The brain health collaboration will also explore pathways to integrate Spectris into programs serving dual-eligible Medicare and Medicaid populations, an area where Alzheimer’s disease places significant clinical and economic burden. The collaboration will seek to generate clinical and health economics data to better understand the cost-effectiveness of noninvasive neuromodulation therapies and their role within value-based care models, including potential exploration of coverage pathways with payers. Together, Cognito and Ochsner aim to develop a new framework for brain health measurement, care delivery, and evidence generation, helping to accelerate the translation of innovative therapies from research to real-world clinical practice. n nursing leadership and management from West- ern Governors University. She is certified in nurs- ing professional development. FMOL Health Earns Gallup Ex- ceptional Workplace Awards FMOL Health announced that it has been hon- ored by Gallup with two top distinctions: the Gal- lup Exceptional Workplace Award for engage- ment and the Gallup Exceptional Workplace Award for strengths-based culture. Manning Family Children’s Earns Cribs for Kids Infant Safe Sleep Hospital Certification Manning Family Children’s has achieved certifi- cation as a Gold Level Cribs for Kids National Safe Sleep Hospital. This certification recognizes the hospital’s healthcare teammembers’ commitment to best practices in infant safe sleep. By earning this certification, Manning Family Children’s dem- onstrates adherence to rigorous guidelines by the Cribs for Kids National Safe Sleep Hospital Certi- fication Program. Oceans Healthcare Names Cady Pruitt Hospital CEO for Baton Rouge Cady Pruitt, LCSW-BACS, MHA, has been named the CEO for Oceans Behavioral Hospital in Baton Rouge. Pruitt joined Oceans Healthcare in 2021 at Loui- siana Behavioral Health, where she served as clin- ical services director before being selected for the inaugural Chief Operating Officer Fellowship Program. Pruitt has a master’s degree in health administration from Louisiana State University Shreveport and is a licensed clinical social worker. Woman’s Hospital is First in the U.S. to Launch International Study to ImproveMaternal Health Woman’s Hospital is partnering with Baymatob on a clinical trial focused on improving maternal health with the Oli wearable sensor. Women wear the device during labor to test its ability to detect early warning signs of postpartum hemorrhage, which is the leading cause of preventable mater- nal death globally. After promising pilot study results, the Australian-based company began an international trial with the goal of enrolling 1,000 women. Woman’s Hospital is the first site in the United States to begin the study and to date has enrolled more than 130 patients. “Woman’s is dedicated to our mission of improving the lives of women and infants, and this study aligns with the work we do every day,” said Robert Moore, MD, Woman’s chief medical officer. “We have a robust research program and when our team became aware of this study, we knew it could potentially provide pivotal informa- tion for our patients and physicians. We are in the data collection phase and honored by all of the patients who are participating.” Baymatob is an AI-guided maternal and fetal diagnostics company founded by Sarah McDon- ald, PhD, who developed the monitor after the traumatic birth of her son, Ollie, in 2013. She became determined to prevent other women from having to experience the same thing. The need for technological advancements to improve birth outcomes is critical. In current med- ical practice, a laboring woman’s risk for hemor- rhage is measured only by a questionnaire based on a patient’s medical history. In contrast, the Oli wearable sensor is placed on the mother’s belly during labor and collects minute-by-minute infor- mation about her body and her baby. That infor- mation is fed into the device to give a doctor a real-time understanding of the mother’s risk for hemorrhage. The Oli Study is taking place at five sites across the country: Woman’s Hospital (Louisiana), Uni- versity of Colorado Anschutz Medical Campus, Columbia University Irving Medical Center (New York), The Ohio State University Wexner Medical Allyson Bennett, MSN, RN